Abstract digital network visualization with glowing nodes and interconnected lines, representing data flow and connectivity.

Extending Trial Value with Long-Term Benefit–Risk Simulation in Prostate Cancer

1 minute read

Published: July 13th, 2026

Demonstrating short-term efficacy is no longer enough, regulators increasingly require a clear understanding of long-term outcomes and benefit–risk balance. Translating Phase 3 trial data into long-term, real-world insights remains a major challenge, particularly when evaluating trade-offs between disease progression and treatment-related adverse events.

Download our case study to learn how advanced modelling and simulation approaches extend trial data beyond its original scope, helping organizations address regulatory uncertainty and support successful label definition.

What You’ll Learn

In this case study, you’ll discover how a leading pharmaceutical organization:

Extended Phase 3 trial data using integrated disease progression modelling

Simulated long-term benefit–risk outcomes across multiple treatment strategies

Quantified trade-offs between disease progression and adverse events

Combined randomized controlled trial and real-world data for stronger evidence generation

Identified optimal patient subgroups to support regulatory positioning and label strategy

Related articles

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

November 16th, 2026 1 minute read

When clinical development programs face quality concerns, resource shortages, or submission risks, sponsors need a pa...

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

November 16th, 2026 1 minute read

When a bioequivalence study fails to meet regulatory criteria, understanding why is critical for successful developme...

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

November 16th, 2026 1 minute read

Data Monitoring Committees play a vital role in safeguarding patient safety and supporting informed decision-making t...